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Available online 20 February 2016Introduction:Depression and anxiety are common among patients withmultiple sclerosis (MS) and are frequent-
ly present at the time of MS diagnosis.
Methods: POSIDONIAwas a 12-month, observational, prospective study conducted in Italy to evaluate the impact
of disease-modifying treatment (DMT) on emotional burden in patients with recently-diagnosedMS. The Hospi-
tal Anxiety and Depression Scale (HADS), specifically HADS anxiety (HADS-A) and depression (HADS-D) sub-
scale scores, the Short-Form 36 Health Survey (SF-36) and the Impact of Event Scale – Revised (IES-R) were
used to measure patient-reported outcomes. The Hamilton Depression Rating Scale (HDRS), HDRS-17, was
used as ameasure of healthcare provider-reported outcomes. The primary study outcomewas change frombase-
line in feelings of anxiety and depression over 12 months (via HADS).
Results: Of 250 enrolled patients, 222 (88.8%) completed the study. At baseline, mean HADS total, HADS-A and
HADS-D subscale scores were within the normal range. There were no significant changes over time in mean
HADS total and HADS-A and HADS-D subscale scores, although the subgroup of patients with baseline scores in-
dicative of anxiety or depression tended to improve over time. Both the HDRS and IES-R total scores improved
over time, but there were no statistically significant changes in SF-36.
Conclusion: In the patient population of the POSIDONIA study depression and anxiety were present in a minority
of patients thus not allowing to detect the impact of starting DMT.HoweverDMT appears to have a positive effect
in patients with measurable anxiety or depression at baseline.
© 2016 Published by Elsevier B.V.Keywords:
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Multiple sclerosis (MS) is a chronic and potentially highly disabling
condition [1]. It may be responsible for considerable personal, social
and economic consequences, and have a significant impact on health-
related quality of life (HR-QOL) [1].edale di Fidenza, Via Don EnricoNotably, depression and anxiety are common in patients with MS
and occur substantially more often in patients withMS than in the gen-
eral population [2,3]. The prevalence of depression among patients with
MS has been estimated to be 11% to 50% [4–9], and anxiety to be 20% to
40% [4,5,8,9]. Causes of depression and anxiety in this patient popula-
tion include MS-related processes, genetic and environment-related
predisposition, normal grieving and adjustment to loss [10,11]. Al-
though depression and anxiety tend to worsen as physical disability in-
creases [12], psychiatric comorbidities such as depression and anxiety
are frequently present at the time of MS diagnosis [2,3,8,13].
106 E. Montanari et al. / Journal of the Neurological Sciences 364 (2016) 105–109Given that MS is characterized by unpredictable variations in symp-
toms, severity and progression [1], uncertainty about their illness is a
common feeling in patients with MS, and may contribute to anxiety
and depression. Recognizing andmanaging emotional needs is a key as-
pect of patient-centred care in MS [14]. Medication use may reduce un-
certainty and distress, as patients may perceive that, through
medication use, they are doing something to control the progression
of their disease.
POSIDONIA (Prospective, Observational Study evaluating Impact of
DMT treatment On the emotioNal burden in recently dIAgnosed multi-
ple sclerosis patients) was a 12-month, prospective observational study
that aimed to evaluate the impact of disease-modifying treatment
(DMT) on emotional burden (changes in feelings of anxiety and depres-
sion) in patients with recently-diagnosed MS.
2. Methods
2.1. Patients
The POSIDONIA studywas conducted in patients diagnosedwithMS
whowerewilling to be treatedwith DMT, following clinical practice. El-
igible patients were required to have a confirmed and documented re-
cent diagnosis of MS (as defined by revised McDonald criteria [15]),
with a relapsing-remitting disease course, aged 18–65 years and had
initiated DMT at the investigator's decision. In addition, they had to be
able to sign and date a written informed consent form prior to entering
the study and be willing and able to comply with the protocol require-
ments for the duration of the study. Patients who had received any pre-
vious treatment with any DMT were excluded, as were those who had
used experimental treatment, investigational drugs or immunosuppres-
sants (including mitoxantrone) prior to the baseline visit. Women who
were pregnant or breastfeedingwere also excluded, as were those with
an insufficient ability to read, write, communicate and understand pa-
tient questionnaires.
2.2. Study design
This was an observational, prospective study conducted in 39 cen-
tres in Italy. The decision to utilise DMT was made by the treating phy-
sician following usual clinical practice. Patients were followed for
12 months, with data collected at baseline (week 0, before treatment),
and at two follow-up visits at 6 months (±2 weeks) [visit 2] and
12months (±2weeks) [visit 3]. A case report formdesigned specifically
for the study was used by physicians to record sociodemographic and
clinical variables (obtained by reviewing medical records or taking the
patient's history). Sociodemographic variables included age, sex, and
level of educational attainment. Clinical variables recorded were: date
of first MS-related medical visit; duration of first MS symptoms; date
of MS diagnosis confirmation; type of MS; currently prescribed DMT
and dose of treatment; co-morbidities; co-medication; data on physical
and neurological examination.
There were three patient-reported outcomes investigated in this
study. The first utilized the Hospital Anxiety and Depression Scale
(HADS), specifically looking at HADS anxiety (HADS-A) and depression
(HADS-D) subscale scores, which range from 0 (no symptoms) to 21
(most severe symptoms). A HADS-A and HADS-D score of ≥8 indicates
a high risk of anxiety and depressive disorder in MS patients [16]. The
Short-Form 36 Health Survey (SF-36) was also used. This comprises
physical health scales (physical functioning, role-physical, bodily pain
and general health) and mental health scales (vitality, social function-
ing, role-emotional and mental health); scores range from 0 (poor
health) to 100 (optimal health). The third tool used was the Impact of
Event Scale – Revised (IES-R), comprising 22 questions which examine
the psychological stress of having MS by focusing on the intensity of
thoughts and feelings relating to MS within the previous 7 days. Addi-
tionally, investigator-reported outcomes were assessed using theHamilton Depression Rating Scale (HDRS), HDRS-17, which assesses
17 items, with a maximum total score of 52; a total score of 0–7 is con-
sidered normal, whereas a total score of ≥18 indicates substantial de-
pression. Data on compliance, concomitant medication use, reported
adverse events and reported serious adverse events were also collected.
The primary study objective was change from baseline in feelings of
anxiety and depression over 12 months, assessed by HADS. HADS is a
screening tool with robust psychometric properties, suitable for use in
subjects with medical condition as it omits items assessing somatic
symptoms, and is widely-used in MS patients. Secondary objectives
were changes in feeling of depression, assessed by HDRS, health-
related quality of life, assessed by SF-36, and disease-related psycholog-
ical distress, assessed by IES-R.
2.3. Study conduct
All study participants providedwritten informed consent. The study
adhered to the tenets of the Declaration of Helsinki and to International
Guidelines for Ethical Review of Epidemiological Studies; it was con-
ducted in accordance with national/local laws/regulations. The study
protocol was approved by the Independent Ethics Committee at each
participating site. The study was sponsored by Teva Italia.
2.4. Statistical analysis
The primary objectivewas to evaluate change in anxiety and depres-
sion in patients with recently-diagnosed MS, assessed using HADS.
Changes in HADS total and subscale scores over time were estimated
by using mixed factorial analysis of variance for repeated measure-
ments. Additionally, a logistic regression model was used to investigate
associations between HADS-D and HADS-A subscale scores of ≥8 at
baseline and prespecified covariates (such as age, sex, time sincefirst di-
agnosis, type of DMT and level of disease-related distress) and other
variables. An exploratory analysis examined score changes in patients
with a baseline HADS score indicative of depression and anxiety versus
patients with HADS-D or HADS-A subscale scores of b8 or HADS total
scores of b16. Changes in HDRS, SF-36 version 2 and IES scores over
time were also assessed, using mixed factorial analysis of variance for
repeated measurements. To ensure consistency with other published
trials inMS, items on the SF-36were scored using the original 0–100 al-
gorithms, instead of the norm-based scoring algorithms.
Primary and secondary objective analyses were conducted in the
per-protocol population, comprising all included patients with all as-
sessments (completers), independently from protocol violations. For
all analyses, p-values of b0.05 were considered statistically significant.
Based on previous experience [8], it was expected that with a de-
crease in the HADS total score of 1 point at 12 months (with a standard
deviation of 5 points), it would be possible to calculate an effect size of
0.20. A sample size of 200 patients would have power of 80%with a sig-
nificance level of 0.05 (two-sided test) to demonstrate an effect size of
0.20. Allowing for a drop-out rate of 20%, a total of 250 patients had to
be enrolled.
2.4.1. Missing data
Unless otherwise stated, patientswithmissingdatawere not consid-
ered in the calculations of percentages. For analysis of the primary and
main secondary endpoint, where the total or the subtotals of the rating
scales was missing owing to missed answers to less than the 50% of the
items, the totals or subtotals have been calculated by the mean of the
filled items. Missing totals or subtotals of the rating scale owing to a
non-monotonic pattern (i.e. missing value at visit 2 but present data
at visit 1 and 3) were determined by interpolation between the values
present at the two adjacent visits. For the HADS total and subscales,
the analysis was performed via SAS PROC MIXED by fitting general lin-
ear and random coefficients general linear models with several
variance-covariance matrix patterns (e.g. variance components,
Table 2
Type of disease-modifying treatment (DMT) prescribed initially and after discontinuation,
values are n (%).
Type of treatment initially prescribed (n = 250)
Glatiramer acetate (Copaxone®) 118 (47.2)
Interferon-β-1a
Avonex® 49 (19.6)
Rebif® 22 29 (11.6)
Rebif® 44 17 (6.8)
Rebif® 22 + 44 6 (2.4)
Interferon-β-1b
Betaferon® 19 (7.6)
Extavia® 8 (3.2)
Azathioprine 2 (0.8)
Nonea 2 (0.8)
Discontinuation of DMT treatment Visit 2 Visit 3
Patients with one DMT discontinuation 25 25
Total number of discontinuations 29 26
Discontinuation of DMTb Visit 2 Visit 3
DMT restarted 3 (10.3) 6 (23.1)
New DMT started 21 (72.4) 10 (38.5)
No new DMT started 5 (17.2) 10 (38.5)
New treatment Visit 2 Visit 3
Avonex® 6 (28.6) 1 (10.0)
Azathioprine 1 (4.8) 0 (0)
Betaferon® 2 (9.5) 0 (0)
Copaxone® 6 (28.6) 3 (30.0)
Rebif® 22 1 (4.8) 2 (20.0)
Rebif® 44 5 (23.8) 3 (30.0)
Tysabri® 0 (0) 1 (10.0)
a These patients dropped out of the study, did not receive any treatment and were not
included in the per-protocol analysis.
b Percentages are calculated on number of interruptions.
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other scales (and subscales) the analyses was performed for all patients
with complete data (at all three visits) bymean of SAS PROC GLM (gen-
eral linear model).
3. Results
3.1. Study participants
A total of 250 patients were enrolled in the study and 222 (88.8%)
completed the study, representing the per-protocol population. Of the
28 (11.2%) patients who did not complete the study, 4 were lost to
follow-up, 2 discontinued because of adverse events, 1 withdrew con-
sent and ‘other’ reasons were recorded for the remaining 21 patients.
Patient demographic data and baseline disease characteristics are
shown in Table 1. Baseline characteristics were generally similar be-
tween women and men, although there was a trend for younger age
of disease onset in women (mean age at diagnosis of 34.84 years in
women and 37.38 years in men; p = 0.064). Mean baseline score of
the Hamilton Depression Rating Scale (HDRS) and of the total score
and subscales of the HADS were below the cut-off score for anxiety
and depression. The mean HADS-A score (6.20 ± 3.99 vs. 4.22 ± 3.41;
p = 0.007) and the mean total HADS score (12.27 ± 6.10 vs. 9.94 ±
5.21) were statistically significantly higher in women than in men. At
baseline only 27% of patients had a HADS-A score ≥ 8 and 23% a
HADS-D score ≥ 8. Patients included in the study were at an initial dis-
ease stage with mild symptoms. Out of the 250 included patients, 219
had a disease duration shorter than one year, 11 patients between one
and two years. Twenty 20 patients had a disease longer than 2 years
but had not previously received DMT. Expanded Disability Status Scale
(EDSS) scores at baseline are shown in Table 1. EDSS score remained
stable over the course of the study.
All patients started treatment with a single DMT (Table 2). Approx-
imately half of the patients received glatiramer acetate and approxi-
mately half received interferon-β (47.2 and 51.2%, respectively). The
majority of patients received DMT without modification during the
study. A total of 25 (10%) patients had at least one DMT discontinuation
between baseline and visit 2 (total of 29 discontinuations) and 25 (10%)
patients had at least one DMT discontinuation between visit 2 and visit
3 (total of 26 discontinuations). Among these patients, only 15 did not
restart DMT during the study and of these, 10 withdrew from the
study. In the remaining cases the same DMT was resumed or another
DMT was started.Table 1
Baseline demographic and disease characteristics.
Characteristic
Gender, n (%) [n = 250]
Female 186 (74.4)
Male 64 (25.6)
Age, years [n = 250]
Mean (SD) 36.41 (9.43)
Median (range) 36.00 (18.00–60.00)
Age at first MS symptom, years [n = 245]
Mean (SD) 33.31 (9.07)
Median (range) 31.74 (16.68–58.71)
Age at MS diagnosis [n = 249]
Mean (SD) 35.49 (9.48)
Median (range) 34.87 (17.81–58.98)
Age at last MS exacerbation [n = 235]
Mean (SD) 35.94 (9.26)
Median (range) 35.73 (17.87–58.71)
EDSS total score [n = 244]
Mean (SD) 1.58 (1.06)
Median (range) 1.50 (0.00–5.50)
Mild disability (EDSS 0–4.5), n 242
Moderate disability (EDSS 5.0–6.5), n 2
EDSS, Expanded Disability Status Scale; MS, multiple sclerosis.Adverse events, lack of efficacy and ‘other’ were the reason for dis-
continuation in 11, 9 and 9 patients, respectively, between baseline
and visit 2, and in 11, 6 and 9 patients, respectively, between visit 2
and visit 3. During the study, at least one additional concomitant medi-
cation was administered to 134 patients. Corticosteroids for MS relapse
were administered to almost 30% of patients, with methylprednisolone
administered in 18.5% of cases.3.2. Primary objective
At baseline, mean HADS total and HADS-A and HADS-D subscale
scores were within the normal range (Table 3). There were no signifi-
cant changes over time in mean HADS total and HADS-A and HADS-D
subscale scores (Table 3). There was no statistically significant interac-
tion between changes in HADS scores over time and the two main
types of DMT (glatiramer acetate and interferon-β) [p-value for
interaction = 0.1677].
Logistic regression analysis demonstrated that, at baseline, the SF-36
vitality (p b 0.0001) and mental health (p= 0.0061) domains were in-
dependent predictors of a HADS-D subscale score of ≥8. For the HADS-A
subscale, logistic regression analysis found that independent predictors
at baseline that were significantly associated with a HADS-A subscale
score of ≥8 were the SF-36 role-physical (p = 0.0522), vitality (p =
0.013) and mental health (p b 0.0001) domains, age at diagnosis
(p = 0.0231) and the IES-R total score (p = 0.0009).
Exploratory analysis revealed that patients with baseline scores in-
dicative of anxiety or depression (HADS total score of ≥16 [n = 46],
HADS-A subscale score of ≥8 [n = 55] or HADS-D subscale score of ≥8
[n = 46]) tended to improve over time (Table 4).
Patients with baseline scores in the normal range (HADS total score
of b16 [n = 155], HADS-A subscale score of b8 [n = 146] or HADS-D
subscale score of b8 [n = 155]) tended to worsen over time (Table 4)
although remaining within the normal range. The time-by-group inter-
action was statistically significant (p b 0.0001) for the HADS total score
and the HADS-D and HADS-A subscale scores.
Table 3
Changes in patient-reported outcomes over time.
Baseline Visit 2 Visit 3 Between all times p-value
HADS scores [n = 201]
HADS total score
Mean (SD) 11.60 (6.10) 11.38 (6.20) 11.06 (6.02) 0.5050
Mean change from baseline (SD) 11.60 (6.10) 0.22 (4.77) 0.53 (5.66)
HADS anxiety subscale score
Mean (SD) 5.58 (3.96) 5.46 (4.12) 5.23 (3.90) 0.5063
Mean change from baseline (SD) 0.11 (3.11) 0.34 (3.65)
HADS depression subscale score
Mean (SD) 6.02 (2.73) 5.91 (2.60) 5.83 (2.69) 0.6903
Mean change from baseline (SD) 0.11 (2.30) 0.19 (2.62)
HDRS scores
HDRS total score [n = 214]
Mean (SD) 6.77 (5.96) 5.88 (5.81) 5.63 (5.77) 0.0032
Mean change from baseline (SD) 0.89 (4.42)a 1.14 (5.67)a
IES-R total score [n = 198]
Mean (SD) 1.15 (0.76) 1.03 (0.79) 0.96 (0.78) 0.0009
Mean change from baseline (SD) 0.12 (0.66)b 0.18 (0.73)b
HADS, Hospital Anxiety and Depression Scale; HDRS, Hamilton Depression Rating Scale; IES-R, Impact of Event Scale – Revised; SD, standard deviation.
a p-Value between baseline and visit 2 of 0.0035 and between baseline and visit 3 of 0.0035.
b p-Value between baseline and visit 2 of 0.0182 and between baseline and visit 3 of 0.0006.
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Both the HDRS and IES-R total scores improved over time, with sta-
tistically significant differences seen between all times, between base-
line and visit 2 and between baseline and visit 3 (Table 3). No
significant changes were seen over time for the SF-36 domains of phys-
ical functioning, role-physical, bodily pain, general health, vitality, social
functioning and role-emotional. Changes over time in the SF-36 mental
health domain did not show statistical significance (p = 0.0682).3.4. Adverse events
DMT was generally well tolerated. There was at least one adverse
event reported in 126 (50.4%) patients and at least one serious adverse
event reported in 6 (2.4%) patients. No deathswere reported during the
study.
Discontinuation because of adverse events occurred in 24 (9.6%) pa-
tients anddiscontinuation because of serious adverse events occurred in
2 (0.8%) patients. The most commonly reported adverse events includ-
edMS-related symptoms (27.6%), influenza (14.4%), injection-site reac-
tions (7.6%) and asthenia (4.4%). Adverse events considered related toTable 4
Exploratory analyses of HADS scores over time.
Baseline Visit 2 Visit 3
Patients with baseline scores indicative of anxiety or depressiona tended to
improve
HADS total scores 20.73 (4.28) 18.52 (6.16) 16.67 (5.94)
HADS-A subscale scores
Mean (SD) 10.94 (2.49) 9.30 (4.10) 8.18 (3.39)
HADS-D subscale scores
Mean (SD) 10.11 (2.22) 8.52 (2.92) 8.17 (3.30)
Patients with baseline scores in the normal rangeb tended to worsen over time
HADS total scores 8.88 (3.27) 9.26 (4.36) 9.40 (4.95)
HADS-A subscale scores
Mean (SD) 3.55 (2.05) 4.01 (3.06) 4.12 (3.48)
HADS-D subscale scores
Mean (SD) 4.80 (1.30) 5.11 (1.86) 5.13 (2.01)
HADS, Hospital Anxiety and Depression Scale; SD, standard deviation time by group inter-
action (p b 0.0001).
a HADS total score of ≥16 (n = 46), HADS-A subscale score of ≥8 (n = 55) or HADS-D
subscale score of ≥8 (n = 46).
b HADS total score of b16 (n= 155), HADS-A subscale score of b8 (n= 146) or HADS-
D subscale score of b8 (n = 155).DMT occurred in 66 patients (93 events in total). Out of these, only
twenty-six events were considered to be related to glatiramer acetate;
local injection-site reactions accounted for 17 of these 26 events, with
only one serious adverse event (severe hepatitis) considered to be relat-
ed to glatiramer acetate.
4. Discussion
This study was aimed to investigate, in an observational period of
12 months, the change of feeling of anxiety and depression measured
by theHADSover the time, in order to evaluate the impact of DMT treat-
ment on emotional burden of recently diagnosed MS patients.
Depression and anxiety are often present at the time of diagnosis in
patients with MS. A previous study indicated that anxiety was promi-
nent in the period surrounding the diagnosis of MS, and that HADS-A
scores, but not HADS-D scores, significantly improved over time [8]. In
this study 43% of patient had a baseline HADS-A score ≥ 8 and only
11% a baseline HADS-D score ≥ 8.
In the POSIDONIA study, baseline HADS total, HADS-A and HADS-D
subscale scores were below the cut-off scores for anxiety and depres-
sion, 27% and 23% of patients having a baseline score ≥ 8 for the
HADS-A and HDS-D, respectively. Baseline scores for HDRS indicated
that patients had very mild depressive symptoms, with baseline scores
for IES-R and SF-36 also supporting the presence of only low level im-
pairment. The fact that mean HADS scores were normal at baseline lim-
ited the likelihood of detecting an improvement in depression and
anxiety following the introduction of DMT. Indeed, overall, HADS total
and HADS-A and HADS-D subscale scores did not significantly change
over time. Although largely used in the literature, the choice of the
HADS as primary outcome measure may have not been optimal. The
HADS is an instrument with good psychometric properties in terms of
factor structure, sub-scale intercorrelation, homogeneity and internal
consistency. However it was developed as a screening instrument and
its simple scoring does not allow enough room for change detection,
particularly in the presence of very mild symptoms (floor effect). In-
deed, when comparing the change over time in patients with patholog-
ical levels of anxiety or depression as opposed to non-anxious and non-
depressed patients the positive influence of starting DMT becomes
more evident. This finding however needs to be confirmed in a larger
sample.
Moreover, significant improvements were seen over time in the sec-
ondary objectives of HDRS total scores and IES-R total scores. The fact
that the HDRS – a more complex and wider scale – was more sensitive
to change seems to support the above consideration.
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main scores, although the change in the mental health domain score
was of borderline statistical significance. Overall, DMT was generally
well tolerated in the POSIDONIA study.
Data are limited concerning the effect of DMT on emotional burden
in patients with recently-diagnosed MS. While there has been concern
that immunomodulatory treatment may induce depression [11], rigor-
ous studies have failed to demonstrate an association between
interferon-β or glatiramer acetate and depression [11]. Regarding the
possibility of an improvement in depression and anxiety symptoms
with DMT, data from the current study suggest such treatment may
have a positive role to play. Although the POSIDONIA study did not
meet the primary objective owing to methodological limitations and
to the observational nature of the study, it provides a valuable back-
ground for future research.
5. Conclusions
In the patient population of the POSIDONIA study depression and
anxiety were present in a minority of patients thus not allowing to de-
tect the impact of starting DMT. However DMT appears to have a posi-
tive effect in patientswithmeasurable anxiety or depression at baseline.
DMT was generally well tolerated in patients with recently-
diagnosed MS.
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